The problem with cutaneous squamous cell carcinoma isn't just that cells grow out of control - it's that they suffer a full-blown identity crisis. Your skin cells have one job: be skin. Build a barrier. Stack up in neat layers. Stay put. But sometimes, through a molecular plot twist worthy of a spy thriller, those obedient little bricklayers rip off their hard hats, grab suitcases, and start wandering through your body like rogue freelancers. Scientists just figured out who's been keeping them in line all along - and what happens when that enforcer goes missing.
Meet WWOX: The Bodyguard Nobody Knew About
A research team led by Prof. Rami Aqeilan at Hebrew University of Jerusalem just published a study in PNAS that finally puts a face on one of the key gatekeepers of skin cell identity: a protein called WWOX (WW domain-containing oxidoreductase). WWOX has been on cancer researchers' radar for years as a tumor suppressor that's frequently lost across multiple cancer types (Yang et al., 2025; PMID: 41228229). But its specific day job in the skin? That was a puzzle piece nobody had placed yet.
Here's what makes this finding click into the bigger picture. WWOX doesn't just suppress tumors in some vague, hand-wavy way. It physically protects another protein called p63 - a master transcription factor that basically runs the "be skin" program. Think of p63 as the foreman on a construction site, shouting orders about which keratins to build, which adhesion molecules to install, which structural proteins to lay down. WWOX is the bodyguard standing next to that foreman, keeping the ITCH E3 ubiquitin ligase (yes, that's its actual name) from dragging p63 to the molecular shredder (Bidany-Mizrahi et al., 2026; PMID: 41984841).
No bodyguard? No foreman. No foreman? Construction site chaos.
When the Bodyguard Disappears, Things Get Ugly Fast
The team engineered mice missing both WWOX and p53 (another tumor suppressor - the famous one) in their skin cells. The results were... dramatic. Every single double-knockout mouse developed tumors - 100% penetrance - compared to about 65% in mice missing only p53. And those tumors showed up roughly five months earlier, which in mouse years is basically the difference between "eventually" and "immediately."
But the real red flag wasn't just speed. It was what happened to the tumor cells themselves. Without WWOX stabilizing p63, the cells underwent epithelial-to-mesenchymal transition (EMT) - that identity crisis I mentioned earlier. EMT is the process where well-behaved epithelial cells ditch their sticky, stay-put nature and morph into mobile, invasive mesenchymal cells. It's a normal process during embryonic development and wound healing, but when tumor cells hijack it, you get metastasis (Genenger et al., 2022).
The particularly sneaky part? These WWOX-null tumor cells didn't fully commit to one identity or the other. They adopted a hybrid EMT state - part epithelial, part mesenchymal - which turns out to be the worst of both worlds. Hybrid cells can stick together enough to survive the bloodstream but are mobile enough to colonize distant organs. When researchers injected WWOX-depleted human cSCC cells into mice, they formed significantly larger lung metastases. Pattern recognized: WWOX loss doesn't just make tumors faster, it makes them smarter about spreading.
The Bigger Puzzle: Why This Fits Perfectly
Here's the satisfying "aha" moment. Cutaneous SCC is the second most common skin cancer worldwide, with incidence climbing 2-5% annually (Que et al., 2024). Most cases get caught early and handled with surgery. But a stubborn subset - poorly differentiated, aggressive, treatment-resistant - continues to blindside clinicians. We've known EMT plays a role in this progression, and we've known WWOX is frequently lost in cancers. What we didn't have was the connecting wire between these two observations.
That wire is p63. WWOX stabilizes p63. p63 maintains epithelial identity. Without this axis, cells lose their programming and gain the ability to invade and metastasize. The team confirmed this wasn't just a mouse phenomenon - human tissue microarrays showed WWOX and p63 levels declining together as cSCC advanced from Stage I through Stage III. The correlation was tight enough to suggest both proteins could serve as biomarkers for identifying which early-stage tumors are about to go rogue.
So What Do We Do With This Puzzle Piece?
The therapeutic implications are genuinely interesting. Rather than targeting the tumor cells directly (a strategy cancer has proven annoyingly good at evading), you could potentially restore the identity program. Think of it as less "kill the rebels" and more "remind them they were construction workers." Approaches could include targeting the ITCH ubiquitin ligase to keep p63 around longer, using TGF-beta pathway inhibitors to block EMT signals, or even differentiation-promoting therapies - an approach that's already worked wonders in certain leukemias (Abu-Remaileh et al., 2020; PMID: 32300104).
The WWOX-p63 axis is one of those findings that suddenly makes three other confusing results in the field make sense. And in cancer research, that's when you know you've found a real piece of the puzzle - not just a pretty edge piece, but one of those annoying middle pieces that suddenly connects two whole sections you'd been staring at separately.
References
-
Bidany-Mizrahi T, Maroun K, Mancini M, et al. WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma. Proc Natl Acad Sci U S A. 2026. DOI: 10.1073/pnas.2534844123. PMID: 41984841.
-
Abu-Remaileh M, Dodber A, Ghalwash M, Aqeilan RI. Pleiotropic tumor suppressor functions of WWOX antagonize metastasis. Signal Transduct Target Ther. 2020;5:43. DOI: 10.1038/s41392-020-0136-8. PMID: 32300104.
-
Yang H, Liao B, Zhao J, Li Y. The Role of WWOX in Cancer Progression: Mechanisms and Therapeutic Potential. Cancers. 2025;17(21):3435. DOI: 10.3390/cancers17213435. PMID: 41228229.
-
Genenger B, Perry JR, Ashford B, Ranson M. A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review). Discover Oncol. 2022;13(1):42. DOI: 10.1007/s12672-022-00510-4.
-
Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: An updated review. Cancers. 2024;16(10):1800. DOI: 10.3390/cancers16101800.
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.